--- title: "The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 | PepTracker Pro Blog" description: "Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.'" lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026", "description": "Amylin has become the obesity field's favorite non-GLP-1 mechanism — but almost every amylin drug is an injection. Structure Therapeutics just started first-in-human testing of ACCG-2671, an oral, once-daily small-molecule amylin agonist. Here's what amylin does, why an oral version matters, how ACCG-2671 compares to amycretin, eloralintide, cagrilintide, and petrelintide, and why 'in a Phase 1 trial' is very different from 'available to buy.'", "datePublished": "2026-06-14", "dateModified": "2026-06-14", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026", "item": "https://peptrackerpro.com/blog/oral-amylin-race-accg-2671-vs-amycretin-eloralintide-pill-vs-injection-june-14-2026" } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Blog](/blog)/ The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 Research & Compounds Research & Compounds # The Race to Put Amylin in a Pill: ACCG-2671 Enters the Clinic, and How Oral Amylin Stacks Up Against Injectable Amylin and GLP-1 — June 14, 2026 PepTracker Pro Research Team June 14, 2026 9 min read ## Table of Contents - [Amylin Is the Obesity Field's Favorite Non-GLP-1 Idea — But It's Almost Always an Injection](#section-0) - [What Just Happened: ACCG-2671 Enters First-in-Human Testing](#section-1) - [Pill vs. Injection — and Small Molecule vs. Peptide](#section-2) - [How ACCG-2671 Compares to the Rest of the Amylin Field](#section-3) - [Reading the Evidence Honestly — and the Provenance Point](#section-4) - [What to Watch Next](#section-5) ## Amylin Is the Obesity Field's Favorite Non-GLP-1 Idea — But It's Almost Always an Injection For two years the obesity conversation has been dominated by incretin drugs — GLP-1 agents like semaglutide and tirzepatide. But the most active 'second mechanism' in the pipeline is amylin. Amylin is a hormone the pancreas releases alongside insulin; it tells the brain you're full and slows how fast the stomach empties. Drugmakers like amylin for two reasons: it controls appetite through a pathway separate from GLP-1 (so the two can be combined), and early data suggest amylin agonists may preserve more lean muscle relative to the large weight loss seen with some GLP-1 regimens. The catch is that nearly every amylin drug in development — cagrilintide, eloralintide, petrelintide — is an injectable peptide. That leaves an obvious gap: an amylin drug you can swallow. ## What Just Happened: ACCG-2671 Enters First-in-Human Testing Structure Therapeutics announced in December 2025 that it had begun a first-in-human Phase 1 study of ACCG-2671, an oral, once-daily small-molecule amylin receptor agonist for obesity. The company selected ACCG-2671 as its lead oral amylin candidate a year earlier, in December 2024, and built it with a structure-based drug-discovery platform aimed at reproducing amylin biology in a pill rather than an injection. The Phase 1 study uses single-ascending-dose and multiple-ascending-dose cohorts in both healthy volunteers and people with obesity to measure safety, tolerability, pharmacokinetics, and early pharmacodynamic signals. In preclinical (animal) work, the company reported potent target engagement, robust weight loss on its own, additional weight loss when paired with a GLP-1 drug, a favorable safety profile, and pharmacokinetics suited to once-daily dosing. Crucially, there is no published human efficacy data yet — this is the very first step in human testing. ## Pill vs. Injection — and Small Molecule vs. Peptide Two distinctions make ACCG-2671 worth understanding. First, oral vs. injectable: most amylin agonists are peptides that must be injected because the gut would digest them; an oral small molecule that can survive digestion and still hit the amylin receptor would be far easier to scale and to combine with other oral drugs. This mirrors what orforglipron and oral semaglutide did for the GLP-1 class — moving a proven mechanism from a needle to a tablet. Second, small molecule vs. peptide: although ACCG-2671 targets the same amylin receptor as injectable amylin peptides, it is a small molecule, not a peptide. That is the same category point we make about compounds like SLU-PP-332: shared target, different molecule class, different manufacturing and regulatory path. ## How ACCG-2671 Compares to the Rest of the Amylin Field It helps to place ACCG-2671 on the map. Eloralintide (Eli Lilly) is an injectable selective amylin agonist with Phase 2 data showing dose-dependent weight loss and notably better gastrointestinal tolerability than older amylin peptides. Cagrilintide (Novo Nordisk) is the injectable amylin agonist best known as half of CagriSema. Petrelintide is another injectable long-acting amylin agonist in development. Amycretin (Novo Nordisk) is different again — a single molecule that hits both the GLP-1 and amylin receptors, and it has both injectable and oral forms in testing, with an early oral study reporting about 13% weight loss over 12 weeks. Against that backdrop, ACCG-2671's distinguishing bet is being an oral, small-molecule, amylin-only agent — potentially a clean oral combination partner for oral GLP-1 drugs. But it is also the least mature of these names: eloralintide and amycretin already have human efficacy data, while ACCG-2671 has only just entered Phase 1. ## Reading the Evidence Honestly — and the Provenance Point This is an exciting candidate, not an available product. The weight-loss numbers behind ACCG-2671 so far come from animal studies reported by the developer; the human trial measures safety and dosing first, and efficacy data are still to come. ACCG-2671 is not approved anywhere, is not prescribed, and is not a compounded product — and it is not on the FDA's July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) list. That last point matters because it separates legitimate clinical-stage drug candidates like ACCG-2671 from the 'research chemicals' sold online: a compound being studied by a public company in a registered trial is on a regulated path, but that path does not make it something a consumer can or should obtain. If you see ACCG-2671 (or any amylin 'research peptide') offered for sale, treat it as a red flag — there is no legitimate consumer supply of a drug that only just started Phase 1. ## What to Watch Next Three things will tell us whether the oral-amylin bet pays off. First, Phase 1 tolerability — specifically nausea and vomiting, the limiting side effects of amylin drugs, and whether an oral once-daily molecule controls them. Second, the first human weight-loss signal and how it compares to injectable amylin agonists. Third, the combination angle: whether oral amylin plus oral GLP-1 becomes the next obesity-drug architecture, the way injectable combinations like CagriSema defined the last wave. For readers, the durable takeaway is mechanistic literacy: amylin and GLP-1 are different levers, 'oral' and 'injectable' change access more than mechanism, and 'in a Phase 1 trial' is the beginning of the evidence story — not the end of it. Ready to track your peptide research? [Open PepTracker Pro](https://app.peptrackerpro.com) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. \[1\] Structure Therapeutics — Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 (Dec 17, 2025) [Source](https://www.globenewswire.com/news-release/2025/12/17/3206968/0/en/Structure-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html) 2. \[2\] Structure Therapeutics — Selection of Lead Oral Amylin Candidate ACCG-2671 (Dec 17, 2024) [Source](https://www.globenewswire.com/news-release/2024/12/17/2998609/0/en/Structure-Therapeutics-Announces-Selection-of-Lead-Oral-Small-Molecule-Amylin-Receptor-Agonist-ACCG-2671-for-the-Treatment-of-Obesity.html) 3. \[3\] Bhattachar SN. et al. — Eloralintide, a selective long-acting amylin receptor agonist: Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 2026 [Source](https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70439) 4. \[4\] Eli Lilly — Eloralintide Phase 2 results press release [Source](https://lilly.gcs-web.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated) 5. \[5\] FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting [Source](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. [Read full research disclaimer →](/research-disclaimer) ## Related Articles [![Policy & Pipeline cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) Policy & Pipeline [ ### Telehealth Goes Vertical on Peptides: Noom Acquires Tailor Made Compounding, Hims & Hers Expands Production, and Eloralintide's Combination Era Begins — June 11, 2026 ](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) Telehealth platforms are racing to own regulated peptide supply chains ahead of the FDA's July 23–24 PCAC vote. Noom has acquired 503A pharmacy Tailor Made Compounding to add sermorelin and NAD+ to its formulary, following Hims & Hers' peptide facility purchase. Meanwhile, Eli Lilly's selective amylin agonist eloralintide enters its combination era with a tirzepatide pairing trial reading out late 2026. PepTracker Pro Team June 11, 2026 10 min read noomtailor made compoundinghims and hers [Read](/blog/telehealth-peptide-vertical-integration-noom-tailor-made-hims-eloralintide-tirzepatide-pcac-june-11-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) Research & Compounds [ ### 'Exercise in a Pill' Goes Mainstream: SLU-PP-332, 5-Amino-1MQ, and MOTS-c — and Why the FDA's July PCAC Vote Won't Cover All of Them — June 12, 2026 ](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) A wave of 'exercise mimetic' and mitochondrial metabolic compounds — SLU-PP-332, 5-Amino-1MQ, and MOTS-c — is moving from research-chemical forums into mainstream wellness, with anti-doping labs now building detection assays. But there's a critical distinction buyers miss: only some of these are on the FDA's July 23–24 PCAC compounding review list. We break down the mechanisms, the evidence (almost entirely preclinical), and what the July vote actually changes. PepTracker Pro Team June 12, 2026 9 min read SLU-PP-332exercise mimeticERR agonist [Read](/blog/exercise-mimetic-research-compounds-mainstream-slu-pp-332-5-amino-1mq-mots-c-pcac-june-12-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) Research & Compounds [ ### A Peptide That Targeted Visceral Fat — and Improved Sleep — Without Lean-Mass Loss: What the Pep19 Trial Shows, and How It Differs From GLP-1s — June 13, 2026 ](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) An early human trial of Pep19 — a synthetic intracellular peptide that works through the endocannabinoid system — cut visceral fat by about 17% and improved sleep over 60 days, with no lean-mass loss and no reported side effects. That combination is unusual. Here's what the data actually show, why the endocannabinoid mechanism is both promising and historically fraught, and how Pep19 differs from the GLP-1 and amylin drugs dominating the obesity conversation. PepTracker Pro Team June 13, 2026 9 min read Pep19endocannabinoid peptideendocannabinoid system [Read](/blog/pep19-endocannabinoid-peptide-visceral-fat-sleep-vs-glp1-june-13-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026) Research & Compounds [ ### ASC39: An Oral Amylin Pill Aiming to Match Injectable Amylin Drugs (July 30, 2026) ](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026) The best amylin obesity drugs are injections. ASC39, from Ascletis, is a once-daily pill that matched Eli Lilly's injectable eloralintide on amylin potency, selectivity and weight loss in preclinical tests - and it is being paired with an oral GLP-1 agonist into a single tablet. Here is what is known, and what is not. PepTracker Pro Team July 30, 2026 7 min read ASC39Ascletisamylin [Read](/blog/asc39-ascletis-oral-small-molecule-amylin-selective-receptor-agonist-eloralintide-like-asc30-fdc-obesity-ind-july-30-2026) [![Research & Compounds cover image](/assets/blog-peptide-guides-BQE1jAYz.jpg)](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026) Research & Compounds [ ### MET-233i: The Once-Monthly Amylin Injection Built to Pair With a Monthly GLP-1 (July 31, 2026) ](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026) Most amylin obesity drugs are weekly shots. MET-233i, from Metsera and now Pfizer, is an amylin analog with a ~19-day half-life - the longest reported for the class - that produced up to 8.4% weight loss in Phase 1 and is engineered to be combined with a monthly GLP-1 agonist into one once-monthly injection. Here is what is known, and what is not. PepTracker Pro Team July 31, 2026 7 min read MET-233iMetseraPfizer [Read](/blog/met-233i-metsera-pfizer-once-monthly-amylin-analog-19-day-half-life-met-097i-combination-obesity-july-31-2026) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.